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cu.2012.Abstract A bioactivity-guided investigation of the ethanolic extract (70%) of the stem bark of
Pterocarpus dalbergioides Roxb. ex DC revealed that the butanol fraction possessed potent antihy-
perglycemic and anti-inﬂammatory activities at a dose of 100 mg/kg b.wt. compared to metformin
(150 mg/kg b.wt.) and indomethacin (20 mg/kg b.wt.) respectively. Two phenolic acids viz: gentisic
(1) and gallic (3) acids and isoﬂavone genistin (2) were isolated for the ﬁrst time from the studied
plant adopting a bioactivity-guided fractionation. Identiﬁcation of the isolated compounds was
achieved using physical, chemical and spectroscopic data.
ª 2012 Faculty of Pharmacy, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Pterocarpus is a genus including about 60-70 species belonging
to family Leguminosae.1 Species of this pantropical genus are
widely distributed in the tropics of both hemispheres.1,2
Pterocarpus dalbergioides Roxb. ex DC, is known in English
as Andaman padauk, Indian mahogany, Andaman redwood
or padauk.3 It is native to the Andaman islands in the
Indian ocean.4 Previous research has established the genus
Pterocarpus to be a rich source of polyphenolic compounds.5o.com (C. Michel).
aculty of Pharmacy, Cairo
g by Elsevier
, Cairo University. Production and
07.003Reviewing the current literature, nothing was reported
concerning the chemical investigation of the studied plant
excepting few reports concerning the occurrence of maackiain
and 30-hydroxy formononetin in its wood.51.1. Diabetes mellitus
(DM) is a global disease, found in all nations of the world.6
Systemic inﬂammation is an early process in the pathogenesis
of type 2 diabetes as elevated circulating pro-inﬂammatory
cytokines are observed in patients with postprandial hypergly-
cemia.7 On the other hand, several studies have been found
concerning the antidiabetic8–14 and anti-inﬂammatory15–17
activities of several Pterocarpus species. Nevertheless, only
one report was traced demonstrating the antihyperglycemic ef-
fect of the alcohol extract of the heart wood of P. dalbergioides
Roxb. ex DC18 and to the best of our knowledge nothing was
dealt with its anti-inﬂammatory activity.hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
2 C. Michel et al.Therefore, it was of interest to focus on the evaluation of
the antihyperglycemic and anti-inﬂammatory activities of the
stem bark of P. dalbergioides Roxb. ex DC and characteriza-
tion of the active principles responsible for these activities.
2. Materials and Methods
2.1. Plant material
Samples of P. dalbergioides Roxb. ex DC were collected during
years 2004–2007 from El-Orman Botanical Garden, Giza,
Egypt. Identiﬁcation of the plant material was kindly veriﬁed
by Dr. Wafaa M. Amer, Professor of Taxonomy and Flora,
Faculty of Science, Cairo University. Stem bark was collected,
dried then pulverized and kept in dark coloured container for
investigation. A voucher specimen (no. 2011 008) is kept at the
herbarium of the Pharmacognosy Department, Faculty of
Pharmacy, Cairo University for future reference.
2.2. Animals
Male albino rats of Sprague Dawely strain weighing 130–150 g
were obtained from the animal house colony, National
Research Centre, Giza, Cairo. Animals were kept on standard
laboratory diet and under the same hygienic conditions.
Animal experiments were carried out following the guidelines
of the Animal Ethics Committee of the National Research
Centre.
2.3. Material and apparatus
Carrageenan (Sigma Company, USA) for induction of
inﬂammation, indomethacin (Eipico, Egyptian International
Pharmaceutical Industries Co. under license of Merck) as
anti-inﬂammatory standard, alloxan (Sigma Company, USA)
for induction of diabetes and metformin (CID Co., Egypt) as
antidiabetic standard.
Sephadex LH-20 (Pharmacia) was used for column chro-
matography and silica gel H without gypsum (E-Merck) for
vacuum liquid chromatography (VLC). Thin layer chromatog-
raphy (TLC) was performed on silica gel 60 F254 precoatedTable 1 Effect of single oral dose administration of ethanolic
subfractions of the stem bark of Pterocarpus dalbergioides Roxb. e
(n= 6).
Groups (Diabetic rats
treated with)
Dose
(mg/kg b.wt.)
Blood glucose level (mg/d
Zero time After 2 h
M± S.E M± S.E
Control 1 ml 257.9 ± 13.6 266.2 ±
Metformin 150 259.6 ± 12.6 163.4 ±
Ethanolic extract (70%) 200 251.6 ± 11.5 196.1 ±
Ethyl acetate fraction 100 247.3 ± 9.1 183.9 ±
Butanol fraction 100 251.4 ± 8.9 129.6 ±
Subfraction II 50 251.8 ± 8.6 202.7 ±
Subfraction V 50 261.4 ± 13.2 159.4 ±
Subfraction VI 50 243.1 ± 9.6 172.1 ±
M=mean; S.E = standard error.
* p< 0.01.plates at a layer thickness of 0.2 mm (E-Merck). Solvent sys-
tems, A: chloroform–acetone–formic acid (75:16.5:8.5 v/v/v),
B: ethyl acetate–methanol–water (100:16.5:13.5 v/v/v) were
used. TLC plates were visualized under UV lamp (at kmax
365 nm) before and after exposure to NH3 vapours and spray-
ing with AlCl3, FeCl3 or p-anisaldehyde reagents.
19 UV spectra
were determined in methanol and after using different shift re-
agents20 on Shimadzu UV-1650 PC visible spectrophotometer.
Melting points were determined using Electrothermal 9100
(U.K.) (uncorrected). 1H and 13C NMR spectra were recorded
on Varian Mercury (1H-300 MHz 13C – 75 MHz) for com-
pounds (1) and (3) and Jeol JNM ECA 500 instrument (1H-
500 MHz 13C-125 MHz) for compound (2) using DMSO as
solvent.
2.4. Methods
2.4.1. Preparation of extracts
The powdered stem bark (15 Kg) of P. dalbergioides Roxb. ex
DC. was extracted with 70% ethanol till exhaustion and the
solvent was evaporated under reduced pressure at a tempera-
ture of 40 C to yield dried residue (1000 g). A part of the dried
residue (750 g) was suspended in water and successively ex-
tracted by liquid–liquid fractionation, with petroleum ether
(60–80 C), chloroform, ethyl acetate and n-butanol saturated
with water, respectively. Each solvent was evaporated sepa-
rately under vacuum at a temperature of 40 C to give 35,
114, 30 and 85 g residues.
2.4.2. Pharmacological Study
Ethanolic extract (70%), ethyl acetate, butanol fractions and
butanol VLC subfractions were dissolved in bi-distilled water
by the aid of few drops of tween 80.
2.4.2.1. Toxicity study. LD50 of ethanolic extract (70%) and its
butanol fraction of the stem bark of P. dalbergioides Roxb. ex
DC. was carried out according to Karber’s method.21.
2.4.2.2. Acute antihyperglycemic activity. Induction of Diabetes
in rats followed the method described by Eliasson and Samet22
by using a single i.p. injection of alloxan (150 mg/kg b.wt.).
Blood samples were collected. Results are presented in Table 1.extract (70%), ethyl acetate, butanol fractions and bioactive
x DC on blood glucose levels in alloxan-induced diabetic rats
l)
After 4 h
%of change M± S.E %of change Potency
12.5 – 264.8 ± 11.7 – –
6.1* 37.1 92.3 ± 4.2* 64.4 1
7.4* 22.1 138 ± 6.9* 45.2 0.7
5.7* 25.6 125.8 ± 4.2* 49.1 0.76
3.7* 48.4 118.4 ± 3.1* 52.9 0.82
8.6* 19.5 143.9 ± 5.3* 42.9 0.67
4.2* 39 108.4 ± 4.5* 58.6 0.91
5.8* 29.2 139.7 ± 4.8* 42.5 0.66
Table 3 Acute anti-inﬂammatory effect of ethanolic extract (70%), ethyl acetate, butanol fractions and bioactive subfractions of the
stem bark of Pterocarpus dalbergioides Roxb. ex DC on carrageenan-induced rat paw oedema (n= 6).
Groups Doses (mg/kg b.wt.) After 4 h
%oedema M± S.E % inhibition Potency
Control (saline) 1 ml 61.9 ± 2.1 – –
Indomethacin 20 21.8 ± 0.4* 64.8 1
Ethanolic extract (70%) 200 32.2 ± 0.8* 48 0.74
Ethyl acetate fraction 100 32.6 ± 0.9* 46.8 0.73
Butanol fraction 100 25.8 ± 0.7* 57.9 0.90
Subfraction II 50 24.3 ± 0.4* 60.4 0.93
Subfraction V 50 29.7 ± 0.5* 51.5 0.79
Subfraction VI 50 27.6 ± 0.4* 55 0.84
M=mean; S.E.= standard error.
* p< 0.01.
Table 2 Effect of repeated oral dose administrations of ethanolic extract (70%) and bioactive subfractions of the stem bark of
Pterocarpus dalbergioides Roxb. ex DC on blood glucose levels in alloxan-induced diabetic rats (n= 6).
Groups (Diabetic rats treated with) Dose
(mg/kg b.wt.)
Blood glucose level (mg/dl)
Zero time After 4 weeks After 8 weeks
M± S.E M± S.E %of change M± S.E %of change Potency
Control 1 ml 249.7 ± 9.2 261.3 ± 10.1 – 267.5 ± 8.9 – –
Metformin 150 256.2 ± 11.4 121.8 ± 5.1* 52.5 89.7 ± 2.1* 65 1
Ethanolic extract (70%) 200 244.3 ± 13.1 171.2 ± 9.4* 29.9 129.6 ± 5.3* 47 0.72
Subfraction II 50 258.1 ± 12.4 182.7 ± 4.8* 29.2 137.2 ± 4.3* 46.8 0.72
Subfraction V 50 272.5 ± 9.3 151.7 ± 6.1* 44.3 108.2 ± 6.4* 60.3 0.93
Subfraction VI 50 263.7 ± 11.9 175.4 ± 8.1* 33.5 137.4 ± 6.2* 47.9 0.74
M=mean; S.E = standard error.
* p< 0.01.
Bioactivity-guided fractionation of the stem bark extract of Pterocarpus dalbergioides Roxb. ex Dc growing in Egypt 32.4.2.3. Long term antihyperglycemic activity. Male albino rats
were similarly receiving alloxan to induce diabetes, as previ-
ously described for the acute effect. Results are presented in
Table 2.
Blood glucose levels were determined by Trainder’s glucose
oxidase method.23
2.4.2.4. Anti-inﬂammatory activity. Acute anti-inﬂammatory
activity was evaluated using carrageenan-induced rat paw oe-
dema test.24,25 Male albino rats were treated orally with the
respective doses before induction of oedema as shown in Table
3. Percentages of oedema and inhibition were calculated
respectively according to the following equations.
% oedema ¼ ðwt: of right paw
 wt: of left pawÞx100=Wt: of left paw
% oedema inhibition ¼ ðMc MtÞx100=Mc
Mc is the mean oedema in control rats and Mt is the mean
oedema in treated animals. Results are presented in Table 3.
2.4.2.5. Statistical analysis. All Data were reported as
mean ± standard error (S.E.) or as percentage. Student’s t-test
was used for statistical analysis of data.26 Results with
P< 0.01 were considered as statistically signiﬁcant.2.5. Phytochemical Study
Based on antihyperglycemic, anti-inﬂammatory screening of
both ethyl acetate and butanol fractions, the butanol fraction
(83 g) was chosen to be subjected to fractionation by VLC col-
umn chromatography packed with silica gel H without gypsum
and eluted successively using chloroform, chloroform–ethyl
acetate and ethyl acetate–methanol mixtures. Similar subfrac-
tions were combined together to yield six subfractions (I–VI)
which were subjected to antihyperglycemic, anti-inﬂammatory
screening.
Active fractions (subfraction II, V and VI) were subjected
to further puriﬁcation to isolate the active principles, a part
of subfraction II (870 mg) and V (330 mg) obtained at chloro-
form–ethyl acetate (97:3 to 85:15 v/v) and (45:55 to 30:70 v/v)
were puriﬁed on a sephadex column using methanol–water
mixtures (90:10) and (50:50) to yield compounds 1 (20 mg)
and 2 (19 mg), respectively.
A part of subfraction VI (440 mg) eluted with chloroform–
ethyl acetate (25:75 to 100% ethyl acetate), was puriﬁed on a
sephadex LH-20 column using methanol–water (70:30 v/v) as
eluent to give compound 3 (23 mg).
Compounds 1, 2 and 3 were subjected to physicochemical,
as well as, spectral analysis for identiﬁcation. Compound 2 was
subjected to acid hydrolysis27 and the sugar moiety was iden-
tiﬁed in the hydrolysate.
4 C. Michel et al.3. Results and discussion
The median lethal dose (LD50) of ethanolic (70%) stem bark
extract was 6.9 gm/kg b.wt. suggesting its safety.28 The extract
showed a potent antihyperglycemic activity on blood glucose
levels in alloxan-induced diabetic rats at a dose of 200 mg/kg
b.wt (potencies 0.7 and 0.72 for acute and chronic effects,
respectively) compared to metformin at a dose of 150 mg/kg
b.wt. (Tables 1 and 2). The anti-inﬂammatory activity of the
extract showed pronounced activity as it signiﬁcantly reduced
the oedema after 4 h of administration (potency 0.74) com-
pared to indomethacin at a dose level of 20 mg/kg b.wt. (Table
3).
LD50 of the butanol fraction of the stem bark was 7.4 gm/
kg b.wt. suggesting its safety.28 Based on previous bioactivity
studies (Tables 1–3), the butanol fraction possessed the most
pronounced acute antihyperglycemic activity (potency 0.82)
compared to the ethyl acetate fraction (potency 0.76), and
more potent anti-inﬂammatory activity (potency 0.90 and
0.73 respectively) when compared to their respective standards.
In order to characterize the compounds responsible for these
effects, a bioactivity-guided fractionation of the butanol frac-
tion was carried out.
This fractionation afforded three active subfractions II, V
and VI. Subfraction V showed the most potent acute (0.91)
and long term (0.93) antihyperglycemic activities followed by
subfraction II (potencies 0.67 and 0.72 for acute & long term
effects, respectively) then subfraction VI (potencies 0.66 and
0.74 for acute & long term effects, respectively) at a dose of
50 mg/kg b.wt. when compared to metformin (150 mg/kg b.
wt.). Regarding the anti-inﬂammatory activity, subfraction II
(potency 0.93) was the most potent, followed by subfraction
VI (potency 0.84) and lastly subfraction V (potency 0.79) at
a dose of 50 mg/kg b.wt. when compared to indomethacin
(20 mg/kg b.wt.).
Three compounds viz.: 1, 2 and 3 were isolated from the
bioactive subfraction II, V and VI, respectively. Identiﬁcation
of the isolated compounds was carried out as follows:
Compound 1 (20 mg), off-white needles, soluble in metha-
nol, m.p. 201–203 C, Rf 0.4 in system (B). It exhibited a dark
purple colour under UV light. Spraying with FeCl3 gave
brown colour indicating its phenolic nature.
UV kmax nm; MeOH: 259. EIMS, 70 ev (relative intensity)
m/z: 154 (M+, 29.45%), 136 (M+-18, 100%), 108 (22.43%),
80 (87.83%).1H-NMR (300 MHz, DMSO) d: 6.77 (1H, d,
J= 8.4 Hz, H-3), 7.26 (1H, dd, J= 8.4 Hz, 2.1 Hz, H-4),
7.33 (1H, d, J= 1.8 Hz, H-6). 13C-NMR (75 MHz, DMSO)
d: 167.24 (C‚O), 149.91 (C-2), 144.79 (C-5), 121.79 (C-4),
120.78 (C-3), 116.50 (C-6), 115.07 (C-1).
From these data and by comparing with published
ones29,30, Compound 1 could be identiﬁed as 2, 5-dihydroxy
benzoic acid or 5-hydroxysalicylic acid (Gentisic acid).
Compound 2 (19 mg), yellow powder, soluble in methanol,
m.p. 265–267 C, Rf 0.73 in system (B). It exhibited dark pur-
ple ﬂuorescence in (UV), (UV/NH3) and (UV/AlCl3).
UV kmax nm; MeOH: 260, 329 (sh.); NaOMe 274, 340;
AlCl3; 271, 300 (sh.), 374; AlCl3/HCl; 270, 305 (sh.), 374;
NaoAc; 262, 328 (sh.); NaoAc/H3BO3; 260, 329 (sh.)
1H-NMR (500 MHz, DMSO) d: 8.4 (1H, br s, H-2), 7.4 (2H,
d, J= 8.6 Hz, H-20,H-60), 6.8 (2H, d, J= 8.6 Hz, H-30,H-50),
6.7 (1H, d, J= 1.2 Hz H-8), 6.4 (1H, d, J= 1.2 Hz, H-6),5.07 (1H, d, J= 7.4 Hz, H-100). 13C-NMR (125 MHz, DMSO)
d: 181 (C-4), 163.5 (C-7), 162.1 (C-5), 158 (C-40), 157.7 (C-9),
155.1 (C-2), 130.7 (C-20, C-60), 123 (C-3), 121.5 (C-10), 115.6
(C-30, C-50), 106.6 (C-10), 100.3 (C-100), 100 (C-6), 95 (C-8),
77.6 (C-500), 76.8 (C-300), 73.5 (C-200), 70 (C-400), 61.1 (C-600).
Therefore, compound2 couldbe identiﬁedas5, 7, 40-trihydroxy
isoﬂavone-7-O-glucoside (Genistein-7-O-ß-D-glucopyranoside)
or (Genistin) by comparing the above mentioned data with
published ones.31–34
Compound 3 (23 mg), yellowish-white powder, soluble in
methanol, m.p. 252–254 C, Rf 0.71 in system (B). It exhibited
shiny violet ﬂuoresence under UV light. Spraying with FeCl3
gave blue colour indicating its phenolic nature.
UV kmax nm; MeOH: 272.
1H-NMR (300 MHz, DMSO) d:
6.92 (2H, S, H-2, H-6), 9.25 (broad singlet, three OH at posi-
tion 3, 4, 5).13C-NMR (75 MHz, DMSO) d: 167.36 (C‚O),
145.26 (C-3, C-5), 137.86 (C-4), 120.25 (C-1), 108.84 (C2, C-6).
By comparing the previous data to those published in liter-
ature35,36, compound 3 could be identiﬁed as 3, 4, 5-trihydroxy
benzoic acid (Gallic acid).
This is the ﬁrst report for the isolation of compounds 1, 2
and 3 from P. dalbergioides Roxb. ex DC.
The potent antihyperglycemic and anti-inﬂammatory activ-
ities of the ethanolic extract (70%), butanol fraction and their
bioactive subfractions could be attributed to the high phenolic
content detected in these subfractions which are in good agree-
ment with the reported data for the isolated compounds37–42
which were known to possess such activities.4. Conﬂict of interest
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